Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes

Background— Cyclic guanosine monophosphate (cGMP) is the common second messenger for the cardiovascular effects of nitric oxide (NO) and natriuretic peptides, such as atrial or brain natriuretic peptide, which activate the soluble and particulate forms of guanylyl cyclase, respectively. However, natriuretic peptides and NO donors exert different effects on cardiac and vascular smooth muscle function. We therefore tested whether these differences are due to an intracellular compartmentation of cGMP and evaluated the role of phosphodiesterase (PDE) subtypes in this process. Methods and Results— Subsarcolemmal cGMP signals were monitored in adult rat cardiomyocytes by expression of the rat olfactory cyclic nucleotide–gated (CNG) channel α-subunit and recording of the associated cGMP-gated current (ICNG). Atrial natriuretic peptide (10 nmol/L) or brain natriuretic peptide (10 nmol/L) induced a clear activation of ICNG, whereas NO donors (S-nitroso-N-acetyl-penicillamine, diethylamine NONOate, 3-morpholinosydnonimine, and spermine NO, all at 100 &mgr;mol/L) had little effect. The ICNG current was strongly potentiated by nonselective PDE inhibition with isobutyl methylxanthine (100 &mgr;mol/L) and by the PDE2 inhibitors erythro-9-(2-hydroxy-3-nonyl)adenine (10 &mgr;mol/L) and Bay 60-7550 (50 nmol/L). Surprisingly, sildenafil, a PDE5 inhibitor, produced a dose-dependent increase of ICNG activated by NO donors but had no effect (at 100 nmol/L) on the current elicited by atrial natriuretic peptide. Conclusions— These results indicate that in rat cardiomyocytes (1) the particulate cGMP pool is readily accessible at the plasma membrane, whereas the soluble pool is not; and (2) PDE5 controls the soluble but not the particulate pool, whereas the latter is under the exclusive control of PDE2. Differential spatiotemporal distributions of cGMP may therefore contribute to the specific effects of natriuretic peptides and NO donors on cardiac function.

[1]  W. Linz,et al.  Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase , 2006, Molecular Pharmacology.

[2]  M. Semigran.  Type 5 phosphodiesterase inhibition: the focus shifts to the heart. , 2005, Circulation.

[3]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[4]  S. Reiken,et al.  Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.

[5]  R. Fischmeister,et al.  Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. , 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[6]  L. Langeberg,et al.  The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways , 2005, Nature.

[7]  E. Barrett-Connor,et al.  Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). , 2005, The American journal of cardiology.

[8]  H. Weiss,et al.  Differential Effects of cGMP Produced by Soluble and Particulate Guanylyl Cyclase on Mouse Ventricular Myocytes , 2005, Experimental biology and medicine.

[9]  A. Papapetropoulos,et al.  Soluble guanylyl cyclase: more secrets revealed. , 2005, Cellular signalling.

[10]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[11]  D. Cooper,et al.  Negative Feedback Exerted by cAMP-dependent Protein Kinase and cAMP Phosphodiesterase on Subsarcolemmal cAMP Signals in Intact Cardiac Myocytes , 2004, Journal of Biological Chemistry.

[12]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[13]  R. Schreiber,et al.  Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance , 2004, Neuropharmacology.

[14]  P. Pattanaik,et al.  Structural insights into the regulation and the activation mechanism of mammalian guanylyl cyclases. , 2004, Pharmacology & therapeutics.

[15]  K. Wollert,et al.  Nitric oxide and the enigma of cardiac hypertrophy , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[16]  Suhn Hee Kim,et al.  High and Low Gain Switches for Regulation of cAMP Efflux Concentration: Distinct Roles for Particulate GC- and Soluble GC-cGMP-PDE3 Signaling in Rabbit Atria , 2004, Circulation research.

[17]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[18]  G. Baxter,et al.  Autocrine and paracrine actions of natriuretic peptides in the heart. , 2004, Pharmacology & therapeutics.

[19]  M. Kuhn,et al.  Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. , 2003, Circulation research.

[20]  D. Rodríguez‐Puyol,et al.  Differential relaxing responses to particulate or soluble guanylyl cyclase activation on endothelial cells: a mechanism dependent on PKG-I alpha activation by NO/cGMP. , 2003, American journal of physiology. Cell physiology.

[21]  Hisham S. Elbatarny,et al.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. , 2003, Molecular pharmacology.

[22]  J. Beavo,et al.  Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F , 2003 .

[23]  R. Fischmeister,et al.  Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following β2‐adrenergic stimulation of ICa,L in frog ventricular myocytes , 2003, The Journal of physiology.

[24]  F. Romano,et al.  Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP‐elevated L‐type calcium current in guinea‐pig ventricular myocytes , 2003, British journal of pharmacology.

[25]  R. Ritchie,et al.  Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. , 2003, Cardiovascular research.

[26]  A. Y. Wu,et al.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  U. Kaupp,et al.  Cyclic nucleotide-gated ion channels. , 2002, Physiological reviews.

[28]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  B. Fleischmann,et al.  Local response of L‐type Ca2+ current to nitric oxide in frog ventricular myocytes , 2001, The Journal of physiology.

[30]  J. Schaack,et al.  In Vivo Assessment of Local Phosphodiesterase Activity Using Tailored Cyclic Nucleotide–Gated Channels as Camp Sensors , 2001, The Journal of general physiology.

[31]  R. Fischmeister,et al.  Cyclic GMP regulation of the L‐type Ca2+ channel current in human atrial myocytes , 2001, The Journal of physiology.

[32]  L. Langeberg,et al.  mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module , 2001, The EMBO journal.

[33]  L. Brunton,et al.  Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. , 2001, Annual review of pharmacology and toxicology.

[34]  Roger Y. Tsien,et al.  Spatiotemporal dynamics of guanosine 3′,5′-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Lawrie,et al.  Activation of the Particulate and Not the Soluble Guanylate Cyclase Leads to the Inhibition of Ca2+ Extrusion through Localized Elevation of cGMP* , 2000, The Journal of Biological Chemistry.

[36]  Thomas C. Rich,et al.  Cyclic Nucleotide–Gated Channels Colocalize with Adenylyl Cyclase in Regions of Restricted Camp Diffusion , 2000, The Journal of general physiology.

[37]  A. Shah,et al.  Paracrine and autocrine effects of nitric oxide on myocardial function. , 2000, Pharmacology & therapeutics.

[38]  D. Cooper,et al.  Adenovirus-mediated Expression of an Olfactory Cyclic Nucleotide-gated Channel Regulates the Endogenous Ca2+-inhibitable Adenylyl Cyclase in C6-2B Glioma Cells* , 1999, The Journal of Biological Chemistry.

[39]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[40]  K. Fujishige,et al.  Novel Alternative Splice Variants of cGMP-binding cGMP-specific Phosphodiesterase* , 1998, The Journal of Biological Chemistry.

[41]  J. Beavo,et al.  Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases* , 1998, The Journal of Biological Chemistry.

[42]  James F. Smith,et al.  Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase* , 1998, The Journal of Biological Chemistry.

[43]  V. Coghlan,et al.  Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs). , 1998, Biochemical and biophysical research communications.

[44]  R. Fischmeister,et al.  cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. , 1997, The Journal of clinical investigation.

[45]  R Fischmeister,et al.  cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Fischmeister,et al.  Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. , 1995, Molecular pharmacology.

[47]  T. Lincoln,et al.  High-affinity binding and localization of the cyclic GMP-dependent protein kinase with the intermediate filament protein vimentin. , 1994, Biochemistry.

[48]  R Fischmeister,et al.  Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. , 1993, The Journal of biological chemistry.

[49]  C. Lugnier,et al.  Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles. , 1992, European journal of pharmacology.

[50]  L. Brunton,et al.  Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. , 1991, Circulation research.

[51]  R Fischmeister,et al.  Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Beavo,et al.  High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. , 1991, The Journal of biological chemistry.

[53]  R. Fischmeister,et al.  Atrial Natriuretic Factor Regulates the Calcium Current in Frog Isolated Cardiac Cells , 1988, Circulation research.

[54]  Jonas JUREVICdIUS,et al.  cAMP compartmentation is responsible for a local activation of cardiac CaZ+ channels by ,8-adrenergic agonists , 2005 .

[55]  D. Cooper,et al.  Negative Feedback Exerted by PKA and cAMP Phosphodiesterase on Subsarcolemmal cAMP Signals in Intact Cardiac Myocytes , 2004 .

[56]  Keith A. Jones,et al.  Differential effects of soluble and particulate guanylyl cyclase on Ca(2+) sensitivity in airway smooth muscle. , 2002, Journal of applied physiology.